2023-11-08 09:45:00
literature
[1] Messerli F, Bangalore S, Mandrola J. β blockers switched to first-line therapy in hypertension. The Lancet, online 13.Oktober 2023, DOI:https://doi.org/10.1016/S0140-6736(23)01733-6
[2] The Task Force for the management of arterial hypertension of the European Society of Hypertension.2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension 2023;41:1874–2071, journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx
[3] The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension 2018;36:1953-2041, DOI: 10.1097/HJH.0000000000001940
[4] Zidek W. Hypertension: Beta blockers no longer first choice. CV 2021;63, doi.org/10.1007/s15027-021-3557-6
[5] You SC et al. Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients – A Large-Scale Multicenter Observational Study. Hypertension. 2021;77(5):1528-38.
[6] A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol 2018;71:e127–e248, www.jacc.org/doi/abs/10.1016/j.jacc.2017.11.006
[7] NVL program from BÄK, KBV, AWMF. S3 guideline National care guideline hypertension. As of June 29, 2023, register.awmf.org/de/leitlinien/detail/nvl-009
1699437142
#Beta #blockers #choice #high #blood #pressure
